Recurrent Hypoglycemia in Type 1 Diabetes (Aim 1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03410277|
Recruitment Status : Recruiting
First Posted : January 25, 2018
Last Update Posted : October 11, 2018
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus, Type 1||Other: Experimental hypoglycemia||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Measurement of Glucose Homeostasis in Human Brain by NMR: Effect of Recurrent Hypoglycemia on Type 1 Diabetes (Aim 1)|
|Actual Study Start Date :||May 24, 2018|
|Estimated Primary Completion Date :||December 2023|
|Estimated Study Completion Date :||December 2023|
Experimental: All Subjects
Other: Experimental hypoglycemia
Experimental hypoglycemia with and without MRI
- Neurochemical response to HG before and after induction of IAH [ Time Frame: 240 Minutes ]The difference in neurochemical response (GABA, glutamate, and glucose) to HG during the first clamp study compared to the neurochemical response to HG after the induction of IAH as determined by the last clamp.
- Antecedent glycemia concentration [ Time Frame: 16 days ]The difference in antecedent glycemia concentration associated with the differences seen in the primary outcome.
- Antecedent physical activity [ Time Frame: 16 days ]The difference in antecedent physical activity associated with the differences seen in the primary outcome.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03410277
|Contact: Anjali Kumar, PA-Cfirstname.lastname@example.org|
|United States, Minnesota|
|University of Minnesota||Recruiting|
|Minneapolis, Minnesota, United States, 55455|
|Contact: Elizabeth R Seaquist, MD 612-624-9176 email@example.com|
|Principal Investigator: Elizabeth R Seaquist, MD|
|Sub-Investigator: Gulin Oz, PhD|
|Principal Investigator:||Elizabeth R Seaquist, MD||University of Minnesota - Clinical and Translational Science Institute|